2.40

3.61% -0.09

After Hours: 2.38 -0.02 -0.83%

Autolus Therapeutics Plc Adr (AUTL)

Overview News Price History Option Chain Financials Discussions Forecast

Autolus Therapeutics Plc Adr stock is traded at $2.40, with a volume of 2.29M. It is down -3.61% in the last 24 hours and up +5.26% over the past month. Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Previous Close:

$2.49

Open:

$2.48

24h Volume:

2.29M

Relative Volume:

1.09

Market Cap:

$638.74M

Revenue:

Net Income/Loss:

$-208.38M

P/E Ratio:

-2.00

EPS:

-1.2

Net Cash Flow:

$-156.57M

1W Performance:

-9.09%

1M Performance:

+5.26%

6M Performance:

+8.60%

1Y Performance:

-48.83%

1-Day Range:

$2.38

$2.50

1-Week Range:

$2.33

$2.66

52-Week Range:

$1.105

$5.00

Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile

Name

Autolus Therapeutics Plc Adr

Sector

Healthcare (1161)

Industry

Biotechnology (646)

Phone

44 20 3829 6230

Address

THE MEDIAWORKS, LONDON

Employee

647

Twitter

Next Earnings Date

2024-12-12

Latest SEC Filings

AUTL's Discussions on Twitter

Compare AUTL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUTL Autolus Therapeutics Plc Adr	2.40	662.68M	0	-208.38M	-156.57M	-1.20
VRTX Vertex Pharmaceuticals Inc	456.87	120.48B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	545.46	59.88B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	392.24	44.31B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	670.33	36.65B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	301.13	32.46B	3.81B	-644.79M	-669.77M	-6.24

Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-18-24	Upgrade	Goldman	Neutral → Buy
Nov-15-24	Upgrade	Redburn Atlantic	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Buy
Mar-27-23	Resumed	Wells Fargo	Overweight
Mar-17-23	Initiated	Bryan Garnier	Buy
Jun-14-21	Upgrade	Jefferies	Hold → Buy
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Dec-28-20	Resumed	H.C. Wainwright	Buy
Jul-31-20	Initiated	JP Morgan	Overweight
Jul-22-20	Initiated	SunTrust	Buy
Apr-22-20	Initiated	Mizuho	Buy
Sep-23-19	Initiated	Needham	Buy
May-17-19	Reiterated	H.C. Wainwright	Buy
Oct-24-18	Initiated	H.C. Wainwright	Buy

View All

Autolus Therapeutics Plc Adr Stock (AUTL) Latest News

Jul 31, 2025

Autolus Therapeutics plc ADR: Weathering Stock Market Storms with 637.41M Market Cap - investchronicle.com

Jul 31, 2025

LyondellBasell Industries NV (LYB) Stock: A Year of Stock Market Ups and Downs - investchronicle.com

Jul 31, 2025

Top chart patterns to watch in Stevanato Group S.p.A.Free High Return Stock Focus With Safety - Newser

Jul 31, 2025

Jul 29, 2025

P 500Real-Time Equity Price Action Analysis - Newser

Jul 29, 2025

Jul 28, 2025

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com

Jul 28, 2025

Jul 25, 2025

TER’s Stock Market Adventure: -40.87% YTD Growth Amidst Volatility - investchronicle.com

Jul 25, 2025

Globe Life Inc (GL) Stock: Navigating a Year of Volatility - investchronicle.com

Jul 25, 2025

Jul 22, 2025

Autolus Therapeutics’ (AUTL) Buy Rating Reaffirmed at Needham & Company LLC - Defense World

Jul 22, 2025

Jul 21, 2025

European Commission approves Autolus’ cell therapy for adult leukemia By Investing.com - Investing.com South Africa

Jul 21, 2025

European Commission approves Autolus’ cell therapy for adult leukemia - Investing.com India

Jul 21, 2025

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) - GlobeNewswire Inc.

Jul 21, 2025

Jul 09, 2025

Cambridge Investment Research Advisors Inc. Sells 2,160 Shares of Invesco KBW Property & Casualty Insurance ETF (NASDAQ:KBWP) - Defense World

Jul 09, 2025

Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World

Jul 09, 2025

1,867 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by DAVENPORT & Co LLC - Defense World

Jul 09, 2025

DAVENPORT & Co LLC Trims Holdings in Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) - Defense World

Jul 09, 2025

Vontobel Holding Ltd. Lowers Holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - Defense World

Jul 09, 2025

Allspring Global Investments Holdings LLC Raises Holdings in Broadstone Net Lease, Inc. (NYSE:BNL) - Defense World

Jul 09, 2025

Wealth Enhancement Advisory Services LLC Takes $258,000 Position in Taylor Morrison Home Corporation (NYSE:TMHC) - Defense World

Jul 09, 2025

Vontobel Holding Ltd. Buys 49,643 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) - Defense World

Jul 09, 2025

TELUS International (Cda) (TSE:TIXT) Trading 2.1% Higher – What’s Next? - Defense World

Jul 09, 2025

Jun 17, 2025

Closing Figures: Autolus Therapeutics plc ADR (AUTL)’s Negative Finish at 2.05, Down -3.30 - DWinneX

Jun 17, 2025

Jun 12, 2025

NOV Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com

Jun 12, 2025

Jun 05, 2025

Autolus shares surge 77% following InvestingPro’s April Fair Value signal By Investing.com - Investing.com India

Jun 05, 2025

May 23, 2025

EMA committee endorses Autolus’ leukemia therapy obe-cel By Investing.com - Investing.com South Africa

May 23, 2025

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens By Stocktwits - Investing.com India

May 23, 2025

EMA committee endorses Autolus’ leukemia therapy obe-cel - Investing.com

May 23, 2025

May 16, 2025